{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:06:49Z","timestamp":1761739609189,"version":"build-2065373602"},"reference-count":111,"publisher":"LIDSEN Publishing Inc","issue":"03","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OBM Transplant"],"accepted":{"date-parts":[[2019,8,29]]},"published-print":{"date-parts":[[2019,9,24]]},"abstract":"<jats:p>Nowadays, hematopoietic stem cell transplantation (HSCT) is a common procedure in hematology units within reference centers, mainly for the treatment of hematological malignancies such as multiple myeloma, lymphoma, and acute leukemia. Nevertheless, HSCT has much wider applications, namely in autoimmune diseases, congenital metabolic defects, and hemoglobinopathies. Thalassemia major and sickle cell disease make up the most frequent hereditary hemoglobinopathies worldwide. Despite advances on the prevention and treatment of complications related to these diseases, the only curative approach available resides in allogeneic HSCT. The main challenges of this treatment remain focused on the toxicity of pre-transplant conditioning regimens and short-term transplant related complications like graft-versus-host disease, infections, and disease recurrence. Thus, it is crucial to establish a balance between the risk vs benefit of HSCT for each patient and follow the available guidelines for both diseases. Recently, gene therapy has become a real alternative to allogeneic HSCT. Recent advances in molecular biology methods have provided more accurate and reliable gene editing techniques such as the CRISP\/CAS9 system. The long-term outcome of gene manipulation procedures remains uncertain, especially in the immune system of the host. This review will focus on HSCT and gene therapy in hereditary hemoglobinopathies.<\/jats:p>","DOI":"10.21926\/obm.transplant.1903086","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T23:51:33Z","timestamp":1569714693000},"page":"1-28","update-policy":"https:\/\/doi.org\/10.21926\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Present and Future Strategies with Curative Intent for Hereditary Hemoglobinopathies"],"prefix":"10.21926","volume":"03","author":[{"given":"Vanessa G.","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Ana Filipa","family":"Saraiva","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Aida Botelho","family":"de Sousa","sequence":"additional","affiliation":[]}],"member":"9387","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: A retrospective observational study. Lancet Haematol. 2015; 2: e91-e100.","DOI":"10.1016\/S2352-3026(15)00028-9"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. 2019. doi: 10.1038\/s41409-019-0465-9.","DOI":"10.1038\/s41409-019-0465-9"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Baldomero H, Aljurf M, Zaidi SZ, Hashmi SK, Ghavamzadeh A, Elhaddad A, et al. Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean\/African region: Comparison with global HSCT indications and trends. Bone Marrow Transplant. 2019; 54: 402-417.","DOI":"10.1038\/s41409-018-0275-5"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017; 390: 311-323.","DOI":"10.1016\/S0140-6736(17)30193-9"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381: 142-151.","DOI":"10.1016\/S0140-6736(12)61229-X"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008; 86: 480-487.","DOI":"10.2471\/BLT.06.036673"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Naik RP, Haywood C. Sickle cell trait diagnosis: Clinical and social implications. Hematology Am Soc Hematol Educ Program. 2015; 2015: 160-167.","DOI":"10.1182\/asheducation-2015.1.160"},{"key":"ref=8","unstructured":"Lavouras LIdC. Hemoglobinopatias: Diagn\u00f3stico laboratorial e sua import\u00e2ncia. Lisbon: University of Lisbon; 2015."},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Costa SN, Madeira S, Sobral MA, Delgadinho G. Hemoglobinopatias em Portugal e a interven\u00e7\u00e3o do m\u00e9dico de fam\u00edlia. Rev Port Med Geral Fam. 2016; 32: 416-424.","DOI":"10.32385\/rpmgf.v32i6.11963"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Chonat S, Quinn CT. Current standards of care and long term outcomes for thalassemia and sickle cell disease. In: Gene and cell therapies for beta-globinopathies. Berlin: Springer; 2017. p. 59-87.","DOI":"10.1007\/978-1-4939-7299-9_3"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Coulet A, Shah N, Hunter L, Barral C, Altman RB. Extraction of genotype-phenotype-drug relationships from text: From entity recognition to bioinformatics application. Biocomputing 2010: World Scientific; 2010. p. 485-487.","DOI":"10.1142\/9789814295291_0051"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017; 376: 1561-1573.","DOI":"10.1056\/NEJMra1510865"},{"key":"ref=13","unstructured":"Ferreira F, Carvalho F, Costa V, Farinha N, Gil-da-Costa MJ, Norton L, et al. Anemias heredit\u00e1rias. Acta Pediatr. 1998; 29: 435-439."},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Algiraigri AH, Wright NA, Paolucci EO, Kassam A. Hydroxyurea for nontransfusion-dependent \u03b2-thalassemia: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2017; 10: 116-125.","DOI":"10.1016\/j.hemonc.2017.02.002"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Piel FB, Weatherall DJ. The \u03b1-thalassemias. N Engl J Med. 2014; 371: 1908-1916.","DOI":"10.1056\/NEJMra1404415"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipek A, Zecca M, et al. Hemopoietic stem cell transplantation in thalassemia: A report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010. Bone Marrow Transplant. 2016; 51: 536.","DOI":"10.1038\/bmt.2015.293"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings III FT. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984; 311: 780-783.","DOI":"10.1056\/NEJM198409203111207"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018; 53: 1139.","DOI":"10.1038\/s41409-018-0153-1"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011; 377: 1663-1672.","DOI":"10.1016\/S0140-6736(11)60355-3"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010; 115: 5300-5311.","DOI":"10.1182\/blood-2009-04-146852"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. Jama. 2014; 312: 1033-1048.","DOI":"10.1001\/jama.2014.10517"},{"key":"ref=22","unstructured":"ASH. State of sickle cell disease, 2016 Report. Am Soc Hematol. 2016: 1-27."},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Maitra P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, et al. Risk factors for mortality in adult patients with sickle cell disease: A meta-analysis of studies in North America and Europe. Haematologica. 2017; 102: 626-636.","DOI":"10.3324\/haematol.2016.153791"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996; 335: 369-376.","DOI":"10.1056\/NEJM199608083350601"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Henig I, Zuckerman T. Hematopoietic stem cell transplantation\u201450 years of evolution and future perspectives. Rambam Maimonides Med J. 2014; 5: e0028.","DOI":"10.5041\/RMMJ.10162"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363: 2091-2101.","DOI":"10.1056\/NEJMoa1004383"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Norkin M, Wingard JR. Recent advances in hematopoietic stem cell transplantation. F1000Res. 2017; 6: 870.","DOI":"10.12688\/f1000research.11233.1"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998; 22: 1-6.","DOI":"10.1038\/sj.bmt.1701291"},{"key":"ref=29","unstructured":"Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report. Blood. 2000; 95: 1918-1924."},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Panepinto JA, Walters MC, Carreras J, Marsh J, Bredeson CN, Gale RP, et al. Matched\u2010related donor transplantation for sickle cell disease: Report from the Center for International Blood and Transplant Research. Br J Haematol. 2007; 137: 479-485.","DOI":"10.1111\/j.1365-2141.2007.06592.x"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007; 110: 2749-2756.","DOI":"10.1182\/blood-2007-03-079665"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Majumdar S, Robertson Z, Robinson A, Starnes S, Iyer R, Megason G. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience. Bone Marrow Transplant. 2010; 45: 895-900.","DOI":"10.1038\/bmt.2009.244"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Dedeken L, L\u00ea PQ, Azzi N, Brachet C, Heijmans C, Huybrechts S, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: A single centre experience of 50 patients. Br J Haematol. 2014; 165: 402-408.","DOI":"10.1111\/bjh.12737"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Lucarelli G, Isgr\u00f2 A, Sodani P, Marziali M, Gaziev J, Paciaroni K, et al. Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Bone Marrow Transplant. 2014; 49: 1376-1381.","DOI":"10.1038\/bmt.2014.167"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Poonkuzhali B, Srivastava A, Quernin M, Dennison D, Aigrain E, Kanagasabapathy A, et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999; 24: 5-11","DOI":"10.1038\/sj.bmt.1701814"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Chandy M, Balasubramanian P, Ramachandran S, Mathews V, George B, Dennison D, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia\u2013the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant. 2005; 36: 839-845.","DOI":"10.1038\/sj.bmt.1705151"},{"key":"ref=37","unstructured":"Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study. Cancer Res. 1990; 50: 6203-6207."},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-L, Saral R, et al. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989; 25: 55-61.","DOI":"10.1007\/BF00694339"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Ljungman P, Hassan M, Bekassy A, Ringden O, \u00d6berg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1997; 20: 909-913.","DOI":"10.1038\/sj.bmt.1700994"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Ferster A, Christophe C, Dan B, Devalck C, Sariban E. Neurologic complications after bone marrow transplantation for sickle cell anemia. Blood. 1995; 86: 408-409.","DOI":"10.1182\/blood.V86.1.408.bloodjournal861408"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Walters MC, Sullivan KM, Bernaudin F, Souillet G, Vannier J-P, Johnson F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood. 1995; 85: 879-884.","DOI":"10.1182\/blood.V85.4.879.bloodjournal854879"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"McPherson M, Hutcherson D, Olson E, Haight A, Horan J, Chiang K. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 2011; 46: 27-33.","DOI":"10.1038\/bmt.2010.60"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Maheshwari S, Kassim A, Yeh R, Domm J, Calder C, Evans M, et al. Targeted Busulfan therapy with a steady-state concentration of 600\u2013700 ng\/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transplant. 2014; 49: 366-369.","DOI":"10.1038\/bmt.2013.188"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Bhatia M, Jin Z, Baker C, Geyer M, Radhakrishnan K, Morris E, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014; 49: 913-920.","DOI":"10.1038\/bmt.2014.84"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Horan JT, Haight A, Dioguardi JL, Brown C, Grizzle A, Shelman C, et al. Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trial. Biol Blood Marrow Transplant. 2015; 21: 900-905.","DOI":"10.1016\/j.bbmt.2015.01.015"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Strocchio L, Zecca M, Comoli P, Mina T, Giorgiani G, Giraldi E, et al. Treosulfan\u2010based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol. 2015; 169: 726-736.","DOI":"10.1111\/bjh.13352"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010; 16: 263-272.","DOI":"10.1016\/j.bbmt.2009.10.005"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. Jama. 2014; 312: 48-56.","DOI":"10.1001\/jama.2014.7192"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"King AA, Kamani N, Bunin N, Sahdev I, Brochstein J, Hayashi RJ, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015; 90: 1093-1098.","DOI":"10.1002\/ajh.24183"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel. haematologica. 2014; 99: 811-820.","DOI":"10.3324\/haematol.2013.099747"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Walters MC, De Castro LM, Sullivan KM, Krishnamurti L, Kamani N, Bredeson C, et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016; 22: 207-211.","DOI":"10.1016\/j.bbmt.2015.10.017"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017; 129: 1548-1556.","DOI":"10.1182\/blood-2016-10-745711"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Saraf SL, Oh AL, Patel PR, Sweiss K, Koshy M, Campbell-Lee S, et al. Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease. Biol Blood Marrow Transplant. 2018; 24: 1759-1765.","DOI":"10.1016\/j.bbmt.2018.03.031"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Seitz R, Hilger A, Heiden M. Bone marrow, peripheral blood, or umbilical cord blood: Does the source of allogeneic hematopoietic progenitor cells matter. J Blood Disord Transfus. 2012. doi: 10.4172\/2155-9864.S1-007.","DOI":"10.4172\/2155-9864.S1-007"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Bashey A, Zhang M-J, McCurdy SR, Martin AS, Argall T, Anasetti C, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell\u2013replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017; 35: 3002-3009.","DOI":"10.1200\/JCO.2017.72.8428"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Krishnamurti L, Abel S, Maiers M, Flesch S. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant. 2003; 31: 547-550.","DOI":"10.1038\/sj.bmt.1703887"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. N Engl J Med. 2014; 371: 339-348.","DOI":"10.1056\/NEJMsa1311707"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012; 18: 1265-1272.","DOI":"10.1016\/j.bbmt.2012.01.019"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Bola\u00f1os-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012; 120: 4285-4291.","DOI":"10.1182\/blood-2012-07-438408"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013; 19: 820-830.","DOI":"10.1016\/j.bbmt.2013.02.010"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016; 128: 2561-2567.","DOI":"10.1182\/blood-2016-05-715870"},{"key":"ref=62","unstructured":"Khazal S, Fernandez P, Benard E, Shoberu B, Manwani D, Mahadeo KM. Allogeneic blood and marrow transplantation for pediatric patients with sickle cell anemia: An institutional experience. Blood. 2017; 130: 4581."},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"de la Fuente J, Dhedin N, Koyama T, Bernaudin F, Kuentz M, Karnik L, et al. Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: Results of an International Learning Collaborative. Biol Blood Marrow Transplant. 2019; 25: 1197-1209.","DOI":"10.1016\/j.bbmt.2018.11.027"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"Fitzhugh CD, Hsieh MM, Taylor T, Coles W, Roskom K, Wilson D, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017; 1: 652-661.","DOI":"10.1182\/bloodadvances.2016002972"},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Pawlowska AB, Cheng JC, Karras NA, Sun W, Wang LD, Bell AD, et al. HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease. Biol Blood Marrow Transplant. 2018; 24: 185-189.","DOI":"10.1016\/j.bbmt.2017.08.039"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Thomas ED, Sanders JE, Buckner CD, Papayannopoulou T, Borgna-Pignatti C, De Stefano P, et al. Marrow transplantation for thalassaemia. Lancet. 1982; 320: 227-229.","DOI":"10.1016\/S0140-6736(82)90319-1"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Lucarelli G, Clift RA, Galimberti M, Polchi P, Angelucci E, Baronciani D, et al. Marrow transplantation for patients with thalassemia: Results in class 3 patients. Blood. 1996; 87: 2082-2088.","DOI":"10.1182\/blood.V87.5.2082.2082"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990; 322: 417-421.","DOI":"10.1056\/NEJM199002153220701"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Lucarelli G, Galimberti M, Giardini C, Polchi P, Angelucci E, Baronciani D, et al. Bone marrow transplantation in thalassemia: The experience of Pesaro. Ann N Y Acad Sci. 1998; 850: 270-275.","DOI":"10.1111\/j.1749-6632.1998.tb10483.x"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Yesilipek MA, Ertem M, Cetin M, \u00d6niz H, Kansoy S, Tanyeli A, et al. HLA\u2010matched family hematopoetic stem cell transplantation in children with beta thalassemia major: The experience of the Turkish Pediatric Bone Marrow Transplantation Group. Pediatr Transplant. 2012; 16: 846-851.","DOI":"10.1111\/j.1399-3046.2012.01778.x"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Lawson SE, Roberts IA, Amrolia P, Dokal I, Szydlo R, Darbyshire PJ. Bone marrow transplantation for \u03b2\u2010thalassaemia major: The UK experience in two paediatric centres. Br J Haematol. 2003; 120: 289-295.","DOI":"10.1046\/j.1365-2141.2003.04065.x"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Mathews V, George B, Deotare U, Lakshmi KM, Viswabandya A, Daniel D, et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with \u03b2 thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13: 889-894.","DOI":"10.1016\/j.bbmt.2007.05.004"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Di Bartolomeo P, Santarone S, Di Bartolomeo E, Olioso P, Bavaro P, Papalinetti G, et al. Long\u2010term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol. 2008; 83: 528-530.","DOI":"10.1002\/ajh.21175"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Ullah K, Khan B, Raza S, Ahmed P, Satti TM, Butt T, et al. Bone marrow transplant cure for \u03b2-thalassaemia major: Initial experience from a developing country. Ann Hematol. 2008; 87: 655-661.","DOI":"10.1007\/s00277-008-0478-8"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li C-K, et al. HLA-matched sibling bone marrow transplantation for \u03b2-thalassemia major. Blood. 2011; 117: 1745-1750.","DOI":"10.1182\/blood-2010-09-306829"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Donnorso MP, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: A prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010; 115: 4597-4604.","DOI":"10.1182\/blood-2010-01-265405"},{"key":"ref=77","doi-asserted-by":"crossref","unstructured":"Li C, Wu X, Feng X, He Y, Liu H, Pei F, et al. A novel conditioning regimen improves outcomes in \u03b2-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012; 120: 3875-3881.","DOI":"10.1182\/blood-2012-03-417998"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004; 104: 1201-1203.","DOI":"10.1182\/blood-2003-08-2800"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: Results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012; 120: 473-476.","DOI":"10.1182\/blood-2012-04-423822"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, et al. Treosulfan-thiotepa-fludarabine\u2013based conditioning regimen for allogeneic transplantation in patients with thalassemia major: A single-center experience from north India. Biol Blood Marrow Transplant. 2013; 19: 492-495.","DOI":"10.1016\/j.bbmt.2012.11.007"},{"key":"ref=81","doi-asserted-by":"crossref","unstructured":"Galambrun C, Pondarr\u00e9 C, Bertrand Y, Loundou A, Bordigoni P, Frange P, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transplant. 2013; 19: 62-68.","DOI":"10.1016\/j.bbmt.2012.08.005"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Lucarelli G, Clift R, Galimberti M, Angelucci E, Giardini C, Baronciani D, et al. Bone marrow transplantation in adult thalassemic patients. Blood. 1999; 93: 1164-1167.","DOI":"10.1182\/blood.V93.4.1164.404k18_1164_1167"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G. Bone marrow transplantation in adults with thalassemia: Treatment and long\u2010term follow\u2010up. Ann N Y Acad Sci. 2005; 1054: 196-205.","DOI":"10.1196\/annals.1345.024"},{"key":"ref=84","doi-asserted-by":"crossref","unstructured":"Hussein AA, Al\u2010Zaben A, Ghatasheh L, Natsheh A, Hammada T, Abdel\u2010Rahman F, et al. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatr Blood Cancer. 2013; 60: 1345-1349.","DOI":"10.1002\/pbc.24493"},{"key":"ref=85","doi-asserted-by":"crossref","unstructured":"Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant. 2008; 14: 301-308.","DOI":"10.1016\/j.bbmt.2007.12.491"},{"key":"ref=86","unstructured":"Iravani M, Tavakoli E, Babaie MH, Ashouri A, Khatami F, Ghavamzadeh A. Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients. Exp Clin Transplant. 2010; 8: 66-73."},{"key":"ref=87","unstructured":"Irfan M, Khalil Hashmi SA, Shamsi T, Farzana T, Ansari S, Panjwani V, et al. \u03b2-Thalassaemia major: Bone marrow versus peripheral blood stem cell transplantation. J Pak Med Assoc. 2008; 58: 107-110."},{"key":"ref=88","doi-asserted-by":"crossref","unstructured":"Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013; 122: 1072-1078.","DOI":"10.1182\/blood-2013-03-489112"},{"key":"ref=89","doi-asserted-by":"crossref","unstructured":"La Nasa G, Giardini C, Argiolu F, Locatelli F, Arras M, De Stefano P, et al. Unrelated donor bone marrow transplantation for thalassemia: The effect of extended haplotypes. Blood. 2002; 99: 4350-4356.","DOI":"10.1182\/blood.V99.12.4350"},{"key":"ref=90","doi-asserted-by":"crossref","unstructured":"Anurathapan U, Pakakasama S, Mekjaruskul P, Sirachainan N, Songdej D, Chuansumrit A, et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transplant. 2014; 20: 2066-2071.","DOI":"10.1016\/j.bbmt.2014.07.016"},{"key":"ref=91","doi-asserted-by":"crossref","unstructured":"Karasu G, Uygun V, Daloglu H, Kilic S, Ozturkmen S, Dincer Z, et al. Hematopoietic stem cell transplantation from unrelated donor in children with beta thalassemia major. Biol Blood Marrow Transplant. 2018; 24: S428-S429.","DOI":"10.1016\/j.bbmt.2017.12.512"},{"key":"ref=92","doi-asserted-by":"crossref","unstructured":"Gaziev J, Isgr\u00f2 A, Sodani P, Paciaroni K, De Angelis G, Marziali M, et al. Haploidentical HSCT for hemoglobinopathies: Improved outcomes with TCR\u03b1\u03b2+\/CD19+-depleted grafts. Blood Adv. 2018; 2: 263-270.","DOI":"10.1182\/bloodadvances.2017012005"},{"key":"ref=93","doi-asserted-by":"crossref","unstructured":"Sodani P, Isgr\u00f2 A, Gaziev J, Paciaroni K, Marziali M, Simone MD, et al. T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients. Pediatr Rep. 2011; 3: e13.","DOI":"10.4081\/pr.2011.s2.e13"},{"key":"ref=94","doi-asserted-by":"crossref","unstructured":"Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, et al. Hematopoietic stem cell transplantation for homozygous \u03b2-thalassemia and \u03b2-thalassemia\/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016; 51: 813-818.","DOI":"10.1038\/bmt.2016.7"},{"key":"ref=95","unstructured":"Rivella S, Sadelain M, editors. Genetic treatment of severe hemoglobinopathies: The combat against transgene variegation and transgene silencing. Semin Hematol. 1998; 35: 112-125."},{"key":"ref=96","doi-asserted-by":"crossref","unstructured":"Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B, et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood. 2007; 110: 1770-1778.","DOI":"10.1182\/blood-2007-01-068759"},{"key":"ref=97","doi-asserted-by":"crossref","unstructured":"Miyoshi H, Bl\u00f6mer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol. 1998; 72: 8150-8157.","DOI":"10.1128\/JVI.72.10.8150-8157.1998"},{"key":"ref=98","doi-asserted-by":"crossref","unstructured":"Urbinati F, Wherley J, Geiger S, Fernandez BC, Kaufman ML, Cooper A, et al. Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease. Cytotherapy. 2017; 19: 1096-1112.","DOI":"10.1016\/j.jcyt.2017.06.002"},{"key":"ref=99","doi-asserted-by":"crossref","unstructured":"Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia. Nature. 2010; 467: 318.","DOI":"10.1038\/nature09328"},{"key":"ref=100","doi-asserted-by":"crossref","unstructured":"Cavazzana M, Ribeil J-A, Payen E, Suarez F, Beuzard Y, Touzot F, et al. Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector. Blood. 2015; 126: 202.","DOI":"10.1182\/blood.V126.23.202.202"},{"key":"ref=101","doi-asserted-by":"crossref","unstructured":"Ribeil J-A, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017; 376: 848-855.","DOI":"10.1056\/NEJMoa1609677"},{"key":"ref=102","doi-asserted-by":"crossref","unstructured":"Thompson AA, Walters MC, Kwiatkowski J, Rasko JE, Ribeil J-A, Hongeng S, et al. Gene therapy in patients with transfusion-dependent \u03b2-thalassemia. N Engl J Med. 2018; 378: 1479-1493.","DOI":"10.1056\/NEJMoa1705342"},{"key":"ref=103","doi-asserted-by":"crossref","unstructured":"Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: An update. Cytotherapy. 2018; 20: 899-910.","DOI":"10.1016\/j.jcyt.2018.04.003"},{"key":"ref=104","doi-asserted-by":"crossref","unstructured":"Sii-Felice K, Giorgi M, Leboulch P, Payen E. Hemoglobin disorders: Lentiviral gene therapy in the starting blocks to enter clinical practice. Exp Hematol. 2018; 64: 12-32.","DOI":"10.1016\/j.exphem.2018.05.004"},{"key":"ref=105","doi-asserted-by":"crossref","unstructured":"Hoban MD, Lumaquin D, Kuo CY, Romero Z, Long J, Ho M, et al. CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol Ther. 2016; 24: 1561-1569.","DOI":"10.1038\/mt.2016.148"},{"key":"ref=106","doi-asserted-by":"crossref","unstructured":"Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, et al. CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature. 2016; 539: 384-389.","DOI":"10.1038\/nature20134"},{"key":"ref=107","doi-asserted-by":"crossref","unstructured":"DeWitt MA, Magis W, Bray NL, Wang T, Berman JR, Urbinati F, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci Transl Med. 2016; 8: 360ra134.","DOI":"10.1126\/scitranslmed.aaf9336"},{"key":"ref=108","doi-asserted-by":"crossref","unstructured":"Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018; 24: 1216.","DOI":"10.1038\/s41591-018-0137-0"},{"key":"ref=109","doi-asserted-by":"crossref","unstructured":"Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008; 322: 1839-1842.","DOI":"10.1126\/science.1165409"},{"key":"ref=110","doi-asserted-by":"crossref","unstructured":"Chevret S, Verlhac S, Ducros-Miralles E, Dalle J-H, De Latour RP, De Montalembert M, et al. Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404). Contemp Clin Trials. 2017; 62: 91-104.","DOI":"10.1016\/j.cct.2017.08.008"},{"key":"ref=111","doi-asserted-by":"crossref","unstructured":"Kauf TL, Coates TD, Huazhi L, Mody\u2010Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009; 84: 323-327.","DOI":"10.1002\/ajh.21408"}],"container-title":["OBM Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.lidsen.com\/journals\/transplantation\/transplantation-03-03-086\/obm.transplant.1903086.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.lidsen.com\/journals\/transplantation\/transplantation-03-03-086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:07:25Z","timestamp":1761718045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.lidsen.com\/journals\/transplantation\/transplantation-03-03-086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":111,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2019]]},"published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.21926\/obm.transplant.1903086","relation":{},"ISSN":["2577-5820"],"issn-type":[{"type":"electronic","value":"2577-5820"}],"subject":[],"published":{"date-parts":[[2019,9,24]]}}}